📋 Key Information Summary
- Amiodarone-induced thyrotoxicosis (AIT) develops in 2–12% of patients on amiodarone in iodine-replete populations such as Australia.
- Two distinct subtypes: Type 1 AIT (excess iodine-driven synthesis in a pre-existing thyroid abnormality) and Type 2 AIT (destructive thyroiditis from direct amiodarone toxicity).
- Type 1 AIT is more common in iodine-deficient regions; Type 2 AIT predominates in iodine-sufficient countries including Australia.
- Mixed-type AIT exists and can be difficult to classify; treat with combination thionamide plus glucocorticoid therapy.
- Colour-flow Doppler ultrasound and interleukin-6 (IL-6) levels are the most useful adjunctive investigations to differentiate Type 1 from Type 2 AIT.
- Thionamides (carbimazole or propylthiouracil) are first-line for Type 1 AIT; glucocorticoids are first-line for Type 2 AIT.
- High-dose potassium perchlorate (short-term ≤6 weeks) may be added to thionamides in Type 1 AIT to block iodide uptake.
- Radioactive iodine (RAI) uptake is generally too low in AIT to be effective; RAI is rarely used.
- Thyroidectomy may be required in refractory cases but carries high peri-operative risk; expert multidisciplinary planning is essential.
- Beta-blockers (preferably propranolol) should be initiated early for symptomatic rate control unless contraindicated.
- Continuation of amiodarone must be weighed against the haemodynamic risk of stopping anti-arrhythmic therapy — a joint cardiology–endocrinology decision.
- All patients commencing amiodarone should have baseline TFTs and 6-monthly monitoring for at least 12 months after cessation (amiodarone has a half-life of 40–55 days).
- Aboriginal and Torres Strait Islander patients face barriers to specialist endocrinology access in remote areas; telehealth and RFDS-supported pathways should be utilised.
🎧 Audio Brief
Introduction & Australian Epidemiology
Amiodarone is a Class III anti-arrhythmic agent widely prescribed in Australia for atrial fibrillation, ventricular tachycardia and heart failure with reduced ejection fraction. Despite its efficacy, amiodarone carries a significant burden of thyroid-related adverse effects owing to two unique pharmacological properties: an exceptionally high iodine content (37% by weight; a single 200 mg tablet delivers approximately 7 mg of inorganic iodide, roughly 45 times the recommended daily intake) and a direct cytotoxic effect on thyroid follicular cells.
Thyroid dysfunction develops in 14–18% of amiodarone-treated patients, split broadly into hypothyroidism (5–10%) and thyrotoxicosis (2–12%). In Australia, where dietary iodine intake is generally adequate (median urinary iodine concentration 100–199 µg/L), amiodarone-induced thyrotoxicosis (AIT) is encountered less frequently than in iodine-deficient regions but remains an important clinical problem because it can precipitate or worsen life-threatening arrhythmias and heart failure.
AIT may present months to years after commencing amiodarone, and may even arise after drug cessation due to the prolonged tissue half-life of 40–55 days (up to 100 days in adipose tissue). Recognition and appropriate subtype classification are critical because the two forms of AIT require fundamentally different treatment strategies. Misclassification can lead to clinical deterioration and excess mortality, which ranges from 3–10% in published series.
Mechanisms: Type 1 vs Type 2 AIT
Understanding the pathophysiological distinction between Type 1 and Type 2 AIT is essential for selecting appropriate therapy. The two subtypes arise from fundamentally different mechanisms, although overlap (mixed-type AIT) is recognised.
Type 1 AIT — Jod–Basedow Phenomenon
Type 1 AIT results from the iodine load provided by amiodarone acting upon a thyroid gland with a pre-existing abnormality — most commonly multinodular goitre, latent Graves' disease or autonomous nodules. The high iodine supply overwhelms the normal Wolff–Chaikoff autoregulatory escape mechanism, permitting autonomous synthesis and release of thyroid hormones. This is termed the Jod–Basedow (iodine-induced) effect.
- More prevalent in areas of prior iodine deficiency (central Europe, parts of South-East Asia).
- Thyroid gland may be enlarged or nodular on examination.
- Radioactive iodine uptake (RAIU) may be low-normal or reduced, but typically >4% (unlike Type 2).
- Colour-flow Doppler ultrasound shows increased vascularity.
- Responds to thionamides, which block new hormone synthesis.
Type 2 AIT — Destructive Thyroiditis
Type 2 AIT is a drug-induced destructive thyroiditis caused by direct cytotoxic effects of amiodarone and its metabolite desethylamiodarone on thyroid follicular cells. Stored pre-formed thyroid hormones are released into the circulation as cells undergo necrosis and apoptosis. There is no new hormone synthesis.
- More prevalent in iodine-sufficient regions, including Australia.
- Thyroid gland is typically normal-sized and non-tender.
- RAIU is markedly suppressed (typically <4%) due to maximal Wolff–Chaikoff effect.
- Colour-flow Doppler ultrasound shows absent or markedly reduced vascularity.
- Responds to glucocorticoids, which suppress inflammation and hormone release.
Mixed-type AIT: Some patients exhibit features of both types simultaneously. This occurs when a pre-existing thyroid abnormality (Type 1 mechanism) coexists with destructive thyroiditis (Type 2 mechanism). Mixed-type AIT is best treated with combination thionamide plus glucocorticoid therapy, and early endocrinology referral is recommended.
Summary Comparison
| Feature | Type 1 AIT | Type 2 AIT |
|---|---|---|
| Mechanism | Excess iodine → new hormone synthesis | Destructive thyroiditis → hormone release |
| Pre-existing thyroid disease | Usually present (MNG, latent Graves') | Usually absent |
| Thyroid gland size | Normal or enlarged / nodular | Normal |
| Colour-flow Doppler | Increased vascularity | Absent / markedly reduced vascularity |
| RAIU | Low-normal or reduced (>4%) | Markedly suppressed (<4%) |
| IL-6 | Normal or mildly elevated | Markedly elevated |
| First-line therapy | Thionamides | Glucocorticoids |
| Outcome after amiodarone withdrawal | May persist for months | Usually self-limited (weeks to months) |
Clinical Features & Investigations
Clinical Presentation
The presentation of AIT is often insidious and may be masked by the beta-blocking properties of amiodarone. Classical symptoms and signs of thyrotoxicosis may be attenuated or absent. A high index of clinical suspicion is therefore essential.
- New or worsening atrial fibrillation / flutter — the most common presenting arrhythmia.
- Recurrent ventricular tachycardia or worsening heart failure in a previously stable patient.
- Palpitations, tremor, heat intolerance, weight loss — may be blunted by amiodarone's adrenergic blockade.
- Unexplained sinus tachycardia or increased ventricular rate on telemetry.
- In severe cases: cardiac decompensation, angina, myocardial infarction.
- Type 2 AIT may present with mild neck discomfort or tenderness; Type 1 is typically painless.
Cardiovascular emergency: AIT can precipitate refractory ventricular arrhythmias and haemodynamic collapse. Any patient on amiodarone with unexplained tachyarrhythmia or heart failure deterioration should have urgent thyroid function tests performed. Early cardiology–endocrinology co-management is recommended.
Investigations
Essential
Thyroid Function Tests (TSH, free T4, free T3)
Suppressed TSH with elevated free T4 and free T3. Free T3 may be disproportionately elevated in Type 2 AIT (pre-formed hormone release). TSH may remain suppressed for weeks after treatment initiation. MBS Item 66710.
Available
Thyroid Receptor Antibodies (TRAb)
May be positive in Type 1 AIT if underlying Graves' disease present. Usually negative in Type 2 AIT. MBS Item 66829.
Available
Thyroid Peroxidase Antibodies (TPO Ab)
Non-specific; may be elevated in either type. Helps identify underlying autoimmune thyroid disease. MBS Item 66828.
Essential
Colour-Flow Doppler Ultrasound (CFDS)
Key investigation for subtype differentiation. Increased vascularity → Type 1; absent vascularity → Type 2. Available at most radiology practices; no MBS restriction. Medicare rebate under ultrasound thyroid item 55063.
Available
Serum Interleukin-6 (IL-6)
Markedly elevated in Type 2 AIT (destructive inflammation). Normal or mildly elevated in Type 1. Not universally available in Australia — request through major hospital laboratories (Royal Adelaide, Westmead, Pathology Queensland).
Specialist
Radioactive Iodine Uptake (RAIU) Scan
Low uptake (<4%) in Type 2; low-normal (>4%) in Type 1. Rarely performed acutely in AIT due to limited clinical utility. Nuclear medicine referral required; available in tertiary centres.
Available
Urinary Iodine Concentration
May confirm high iodine load. Reference range 100–199 µg/L (Australian population median). Not essential for diagnosis but supports clinical picture.
Essential
ECG & Echocardiography
Assess for new or worsening arrhythmia, ventricular function, and pericardial effusion. Essential in all patients with suspected AIT.
Differentiation of AIT Types
Accurate subtype classification is critical because Type 1 and Type 2 AIT require different pharmacological approaches. No single investigation is diagnostic; a combination of clinical, biochemical and imaging features should be used.
Differentiating Algorithm
1
Clinical Assessment
Palpate the thyroid. Nodular or enlarged gland favours Type 1. Non-tender, normal-sized gland favours Type 2. Neck pain suggests Type 2 (destructive).
2
Colour-Flow Doppler Ultrasound
Increased vascularity → Type 1. Absent / markedly reduced vascularity → Type 2. This is the single most useful bedside investigation.
3
IL-6 Level
Markedly elevated (>5 pg/mL) favours Type 2. Normal / mildly elevated favours Type 1. Useful when Doppler is equivocal.
4
Thyroid Autoantibodies
Positive TRAb → underlying Graves' disease → Type 1 AIT. TPO Ab may be present in either type but is non-specific.
5
RAIU Scan (if available)
Uptake >4% → Type 1. Uptake <4% → Type 2. Rarely needed in clinical practice given the above investigations.
When in doubt: If the subtype cannot be confidently classified (mixed-type AIT or equivocal investigations), treat with combined thionamide plus glucocorticoid therapy and refer to an endocrinologist urgently. Do not delay treatment while awaiting classification.
Severity Assessment
Mild
Subclinical or Mild AIT
Suppressed TSH with mildly elevated FT4/FT3. Patient is haemodynamically stable. No new arrhythmia. Minimal symptoms.
Setting: Outpatient — endocrinology clinic within 1–2 weeks
Moderate
Moderate AIT
Significantly elevated FT4/FT3. New or worsening atrial fibrillation. Moderate symptoms (palpitations, tremor, weight loss). Haemodynamically stable.
Setting: Hospital admission — endocrinology ± cardiology consultation
Severe
Severe / Thyroid Storm
Haemodynamic instability. Ventricular tachycardia, acute heart failure, angina, altered consciousness. Burch–Wartofsky score ≥45.
Setting: ICU — urgent multidisciplinary team involvement
Management
Management of AIT requires a dual strategy: controlling the hyperthyroid state and addressing the underlying arrhythmia or cardiac indication for amiodarone. Joint cardiology–endocrinology input is strongly recommended for all cases.
General Measures (All AIT Types)
- Beta-blockade: Initiate propranolol for symptomatic control. If propranolol is contraindicated (severe asthma, decompensated heart failure), consider atenolol or metoprolol. Note: amiodarone's intrinsic beta-blocking effect may limit titration.
- Amiodarone continuation: A joint decision with cardiology. If the arrhythmia is life-threatening and no alternative anti-arrhythmic is suitable, amiodarone should be continued with aggressive treatment of the thyrotoxicosis. If safe to cease, amiodarone withdrawal alone will not rapidly resolve AIT due to prolonged tissue half-life.
- Anticoagulation: Reassess stroke risk if AF/Flutter is present. Treated as per standard AF guidelines (CHA₂DS₂-VASc score).
- Monitor closely: TFTs every 2–4 weeks until euthyroid, then 6–8 weekly during treatment. ECG monitoring in hospitalised patients.
Type 1 AIT — Pharmacotherapy
The goal is to block new thyroid hormone synthesis. High doses of thionamides are typically required because the iodine excess saturates the organification pathway.
Carbimazole
Neo-Mercazole® · Thionamide (blocks organification)
Adult dose
20–40 mg PO daily (higher end of range for AIT). Titrate to response every 4–6 weeks.
Paediatric dose
0.5–1 mg/kg/day PO in divided doses (paediatric endocrinology supervision)
Route
Oral
Key ADRs
Agranulocytosis (0.2–0.5%; check FBC at onset of sore throat), hepatotoxicity, rash
Renal adjustment
No dose adjustment required
PBS status
✔ PBS General Benefit
Propylthiouracil (PTU)
Propycil® · Thionamide (blocks organification + peripheral T4→T3 conversion)
Adult dose
200–400 mg PO daily in divided doses (TDS). Preferred first trimester of pregnancy.
Paediatric dose
5–7 mg/kg/day PO in 3 divided doses
Route
Oral
Key ADRs
Hepatotoxicity (rare but serious; monitor LFTs), agranulocytosis, ANCA vasculitis
Renal adjustment
No dose adjustment required
PBS status
✔ PBS General Benefit
Potassium Perchlorate
Short-term adjunct · Inhibits iodide uptake via NIS blockade
Adult dose
200–1000 mg PO daily (typically 400 mg TDS) for ≤6 weeks only
Route
Oral
Key ADRs
Aplastic anaemia (dose- and duration-dependent; limit to 6 weeks). Monitor FBC weekly.
Availability
Specialist-compounded or imported. Not TGA-registered; arrange through hospital pharmacy.
PBS status
✘ Not PBS listed
Type 2 AIT — Pharmacotherapy
The goal is to suppress inflammation and reduce the release of pre-formed thyroid hormone. Glucocorticoids are the mainstay.
Prednisone
Prednisolone alternatives: Solone®, Panafcortelone® · Glucocorticoid
Adult dose
40–60 mg PO daily for 2–4 weeks, then taper gradually over 2–3 months guided by TFTs
Route
Oral
Duration
2–4 months total. Do not stop abruptly.
Key ADRs
Hyperglycaemia, insomnia, GI upset, osteoporosis with prolonged use. Monitor BSL and consider PPI.
Renal adjustment
No dose adjustment required
PBS status
✔ PBS General Benefit
Dexamethasone
DEXASONE® · Potent glucocorticoid, also inhibits peripheral T4→T3 conversion
Adult dose
2–4 mg PO/IV daily in divided doses (BD–TDS) for severe / refractory cases
Route
Oral or IV
Key ADRs
As per all glucocorticoids; more potent so monitor closely
PBS status
✔ PBS General Benefit
Propranolol — Symptomatic Control (All Types)
Propranolol
Inderal®, Deralin® · Non-selective beta-blocker (also inhibits peripheral T4→T3 conversion)
Adult dose
20–40 mg PO TDS–QID. Titrate to HR <100 bpm. May require 80–160 mg/day in severe thyrotoxicosis.
Paediatric dose
0.5–1 mg/kg/day PO in divided doses
Route
Oral (IV formulation available for acute settings)
Contraindications
Severe asthma, decompensated heart failure (unless tolerated), 2nd/3rd degree heart block, severe bradycardia
PBS status
✔ PBS General Benefit
Mixed-Type / Refractory AIT
- Combined thionamide (carbimazole 40 mg/day) plus glucocorticoid (prednisone 40 mg/day) therapy is recommended when the subtype is unclear or features of both types are present.
- Reassess at 4 weeks. If FT4 is falling, continue current regimen. If not, consider addition of potassium perchlorate (Type 1 component) or escalation of glucocorticoid dose (Type 2 component).
- Plasmapheresis or plasma exchange has been reported in life-threatening refractory AIT to acutely lower circulating thyroid hormones. Available at major tertiary centres (e.g., Royal Melbourne, St Vincent's Sydney, Royal Adelaide). Consider in ICU patients with haemodynamic instability not responding to medical therapy.
Thyroidectomy
Thyroidectomy may be necessary for patients with refractory AIT who cannot be rendered euthyroid despite maximal medical therapy, or when amiodarone cannot be withdrawn and continued AIT poses unacceptable cardiac risk.
Peri-operative risk: Thyroidectomy in uncontrolled AIT carries significant morbidity and mortality (up to 9% in some series). The patient must be rendered as close to euthyroid as possible pre-operatively. Near-total or total thyroidectomy should be performed by an experienced endocrine surgeon in a facility with ICU capability. Pre-operative Lugol's iodine (SSKI) is not effective in Type 2 AIT and may worsen Type 1 AIT. Beta-blocker and glucocorticoid cover is essential peri-operatively.
Quick Reference — Treatment by AIT Type
Type 1 AIT
Carbimazole 20–40 mg/day ± potassium perchlorate 400 mg TDS (≤6 weeks)
Until euthyroid; may require long-term thionamide if amiodarone continued
Consider potassium perchlorate adjunct if inadequate response to thionamide alone
Type 2 AIT
Prednisone 40–60 mg/day → taper over 2–3 months
2–4 months total
Dexamethasone 4 mg/day for severe / refractory cases. Taper guided by FT4 normalisation.
Mixed / Unclassified
Carbimazole 40 mg/day + Prednisone 40 mg/day
Reassess at 4 weeks; adjust based on response
Early endocrinology referral essential. Consider plasmapheresis if life-threatening.
Monitoring
Monitoring during and after treatment of AIT is essential due to the prolonged tissue half-life of amiodarone and the risk of relapse or transition to hypothyroidism.
Baseline
TFTs (TSH, FT4, FT3), FBC, LFTs, UEC, BSL, ECG, echocardiography. Confirm colour-flow Doppler ultrasound performed.
Every 2–4 weeks
TFTs during active treatment phase. FBC weekly if on potassium perchlorate (aplastic anaemia risk). FBC at onset of sore throat if on thionamides (agranulocytosis).
Every 4–6 weeks
During thionamide dose titration. Adjust dose to maintain FT4 in upper-normal range.
Every 2–3 months
During glucocorticoid taper. Watch for transition to hypothyroidism (especially Type 2 AIT → hypothyroid phase).
After amiodarone cessation
Continue TFT monitoring every 6–8 weeks for at least 12 months post-cessation due to prolonged drug elimination. Some patients develop late hypothyroidism.
Long-term
Annual TFTs if euthyroid off amiodarone. More frequent monitoring if on ongoing anti-arrhythmic therapy or if previous AIT.
Transition to hypothyroidism: Type 2 AIT may evolve through a thyrotoxic → euthyroid → hypothyroid sequence as the damaged gland fails to recover. Monitor TSH closely during glucocorticoid taper and after drug cessation. Commence levothyroxine if persistent hypothyroidism develops.
Special Populations
Pregnancy
Propylthiouracil (PTU)
Preferred thionamide in first trimester (lower teratogenicity risk vs carbimazole — aplasia cutis, choanal atresia). Switch to carbimazole after first trimester if preferred due to hepatotoxicity risk of PTU.
Prednisolone
Safe in pregnancy for Type 2 AIT. Use lowest effective dose. Monitor for gestational diabetes.
Propranolol
May be used short-term. Avoid prolonged use (associated with IUGR). Prefer lowest effective dose.
Potassium perchlorate
Contraindicated in pregnancy (causes fetal goitre, hypothyroidism).
Amiodarone in pregnancy
May cause fetal hypothyroidism, bradycardia, goitre. If amiodarone is essential, fetal thyroid monitoring (cordocentesis if indicated) should be discussed with a fetal medicine unit.
Paediatrics
Amiodarone-induced thyroid dysfunction in children
Less common than in adults but follows the same Type 1 / Type 2 classification. Paediatric endocrinology referral is essential. Carbimazole 0.5–1 mg/kg/day is first-line for Type 1 AIT. Prednisolone 1–2 mg/kg/day for Type 2 AIT.
Monitoring
More frequent TFT monitoring recommended (every 1–2 weeks initially) due to narrower therapeutic margin in children.
Elderly
Higher cardiovascular risk
Elderly patients are more susceptible to arrhythmia exacerbation from AIT. Lower threshold for ICU admission. Beta-blocker titration should be cautious due to risk of bradycardia (amiodarone's additive effect).
Glucocorticoid adverse effects
Increased risk of hyperglycaemia, osteoporosis and fractures. Consider bone density monitoring and calcium/vitamin D supplementation if prolonged prednisone course.
Renal Impairment
Thionamides
No dose adjustment required. Carbimazole and PTU are hepatically metabolised.
Potassium perchlorate
Caution in renal impairment — perchlorate is renally excreted. Dose reduction may be necessary. Monitor serum potassium closely (perchlorate contains potassium).
Prednisone
No dose adjustment required. Monitor fluid status and glucose in CKD.
Hepatic Impairment
Carbimazole / PTU
Both are hepatically metabolised and can cause hepatotoxicity. PTU carries a black-box warning for severe hepatic necrosis. Monitor LFTs closely. Use lower doses; consider specialist input. In severe liver disease, potassium perchlorate (if available) plus glucocorticoids may be preferred.
Prednisone
Hepatic activation is required. No dose adjustment in mild–moderate impairment. Use with caution in severe liver disease.
Immunocompromised
Glucocorticoid therapy
Additional immunosuppression from prednisone must be considered in already immunocompromised patients (transplant recipients, HIV, chemotherapy). Monitor for opportunistic infections. Consider Pneumocystis jirovecii prophylaxis if prolonged high-dose steroids.
Agranulocytosis risk
Thionamide-induced agranulocytosis may be harder to detect in patients with baseline cytopenias. Maintain high vigilance and low threshold for FBC.
Aboriginal and Torres Strait Islander Health
Aboriginal and Torres Strait Islander Health Considerations
📚 References
- 1. Martino E, Bartalena L, Bogazzi F, Braverman LE. The effects of amiodarone on the thyroid. Endocrine Reviews. 2001;22(2):240–254.
- 2. Basaria S, Cooper DS. Amiodarone and the thyroid. The American Journal of Medicine. 2005;118(7):706–714.
- 3. Bartalena L, Brogioni S, Grasso L, Bogazzi F, Burelli A, Martino E. Treatment of amiodarone-induced thyrotoxicosis, a difficult challenge: results of a prospective study. Journal of Clinical Endocrinology & Metabolism. 1996;81(8):2930–2933.
- 4. Bogazzi F, Bartalena L, Martino E. Approach to the patient with amiodarone-induced thyrotoxicosis. Journal of Clinical Endocrinology & Metabolism. 2011;96(5):1207–1213.
- 5. Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26(10):1343–1421.
- 6. Kahaly GJ, Bartalena L, Hegedüs L, Leenhardt L, Poppe K, Pearce SH. 2018 European Thyroid Association guideline for the management of Graves' hyperthyroidism. European Thyroid Journal. 2018;7(4):167–186.
- 7. Australian Institute of Health and Welfare (AIHW). Cardiovascular disease in Aboriginal and Torres Strait Islander people. Cat. no. CVD 88. Canberra: AIHW; 2022.
- 8. Tomisti L, Rossi G, Bartalena L, et al. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. European Journal of Endocrinology. 2014;171(3):363–368.
- 9. Royal Australian College of General Practitioners (RACGP). Management of thyroid disorders in general practice. Australian Family Physician. 2017;46(11):810–816.
- 10. Tsang W, Houlden RL. Amiodarone-induced thyrotoxicosis: a review. Canadian Journal of Cardiology. 2009;25(8):421–424.
- 11. Eskes SA, Endert E, Fliers E, et al. Treatment of amiodarone-induced thyrotoxicosis with plasmapheresis. Annals of Internal Medicine. 2012;156(10):725–726.
- 12. National Health and Medical Research Council (NHMRC). Iodine supplementation for pregnant and breastfeeding women. NHRMC Public Statement. Canberra: NHMRC; 2010.